Advertisement
GUTS vs REVB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GUTS is a Hold and REVB is a Buy.
GUTS's RSI Indicator is sitting in oversold zone for 11 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where GUTS advanced for three days, in 104 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
GUTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GUTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GUTS entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GUTS's P/B Ratio (-131.933) is very low in comparison to the industry average of (2.978). P/E Ratio (-1.516) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. GUTS's P/S Ratio (10000.000) is very high in comparison to the industry average of (438.009).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. GUTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GUTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
REVB's RSI Indicator is staying in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
REVB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REVB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for REVB entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.179) is normal, around the industry mean (2.978). P/E Ratio (0.017) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. REVB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
REVB | ||
|---|---|---|
OUTLOOK RATING 1..100 | 52 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 50 | |
P/E GROWTH RATING 1..100 | 1 | |
SEASONALITY SCORE 1..100 | 5 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| GUTS | REVB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Momentum ODDS (%) | N/A | N/A |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Advances ODDS (%) | 6 days ago 85% | N/A |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 87% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GUTS’s FA Score shows that 2 FA rating(s) are green while REVB’s FA Score has 1 green FA rating(s).
- GUTS’s FA Score: 2 green, 3 red.
- REVB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GUTS’s TA Score shows that 4 TA indicator(s) are bullish while REVB’s TA Score has 3 bullish TA indicator(s).
- GUTS’s TA Score: 4 bullish, 2 bearish.
- REVB’s TA Score: 3 bullish, 2 bearish.
Price Growth
GUTS (@Biotechnology) experienced а -68.71% price change this week, while REVB (@Biotechnology) price change was -41.38% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.60%. For the same industry, the average monthly price growth was -14.07%, and the average quarterly price growth was -13.84%.
Reported Earning Dates
GUTS is expected to report earnings on Nov 18, 2026.
REVB is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (+2.60% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GPIX | 55.82 | 0.22 | +0.40% |
| Goldman Sachs S&P 500 Premium Income ETF (GPIX) | |||
| FDTS | 69.27 | 0.05 | +0.08% |
| First Trust Developed Markets ex-US Small Cap AlphaDEX Fund (FDTS) | |||
| RBIL | 49.92 | -0.01 | -0.02% |
| F/m Ultrashort Treasury Inflation-Protected Security (TIPS) ETF (RBIL) | |||
| IAT | 57.09 | -0.51 | -0.89% |
| iShares U.S. Regional Banks ETF (IAT) | |||
| IFED | 45.38 | -0.50 | -1.09% |
| ETRACS IFED Invest with the Fed TR Index ETN due September 15, 2061 (IFED) | |||
REVB and
Correlation & Price change
A.I.dvisor indicates that over the last year, REVB has been closely correlated with INKT. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if REVB jumps, then INKT could also see price increases.
| Ticker / NAME | Correlation To REVB | 1D Price Change % | ||
|---|---|---|---|---|
| REVB | 100% | -6.54% | ||
| INKT - REVB | 80% Closely correlated | -0.11% | ||
| GNPX - REVB | 48% Loosely correlated | -2.37% | ||
| SABS - REVB | 48% Loosely correlated | +2.77% | ||
| GUTS - REVB | 40% Loosely correlated | -10.97% | ||
| ANL - REVB | 33% Loosely correlated | -5.89% | ||
More | ||||